Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Explores AI Content Marketplace With Media Publishers 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
SEATTLE, Dec. 13, 2017 -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index® (Nasdaq:NBI), which will become effective prior to U.S. market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on the Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is re-ranked annually and all securities in the index are listed on the Nasdaq Global Market or the Nasdaq Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. Tucatinib is also being studied in other cancers through investigator initiated studies, including HER2+ metastatic colorectal cancer and earlier lines of HR+/HER2+ metastatic breast cancer. For more information, please visit www.cascadianrx.com.
Source: Cascadian Therapeutics, Inc.
Contact:
Cascadian Therapeutics
Monique Greer
206-801-2107
[email protected]
